Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.58, $0.06 better than the analyst estimate of $1.52. Revenue for the quarter came in at $6.3 billion versus the consensus estimate of $5.86 billion.

GUIDANCE:

Gilead Sciences sees FY2022 EPS of $6.35-$6.75, versus the consensus of $6.57.

• Total product sales between $24.5 billion and $25.0 billion, compared to $23.8 billion and $24.3 billion previously.
• Total product sales, excluding Veklury, between $22.0 billion to $22.5 billion, compared to $21.8 billion and $22.3 billion previously.
• Total Veklury sales of approximately $2.5 billion, compared to approximately $2.0 billion previously.
• Non-GAAP earnings per share between $6.35 and $6.75, compared to $6.20 and $6.70 previously.
• Earnings per share between $2.90 and $3.30, compared to $3.00 and $3.50 previously.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.